The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); HiberCell (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Synologic Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst)
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Lilly (Inst); Guardant Health (Inst); Roche/Genentech (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - Abbvie; AstraZeneca; Biovica; Black Diamond Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Eisai; Infinity Pharmaceuticals; Karyopharm Therapeutics; Kolon Life Sciences; Lengo Therapeutics; Loxo; OnCusp Therapeutics; PACT Pharma; Roche; Seagen; Silverback Therapeutics; Tallac Therapeutics; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
 
Filip Janku
Employment - Monte Rosa Therapeutics
Leadership - Monte Rosa Therapeutics
Stock and Other Ownership Interests - Cardiff Oncology; Monte Rosa Therapeutics
Consulting or Advisory Role - Cardiff Oncology; Deciphera; Fore Biotherapeutics; Fore Biotherapeutics; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunomet; Jazz Pharmaceuticals; Novartis; Novartis; PureTech; Sequenom; Sotio; Synlogic; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Gateway Foundation (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); TRACON Pharma (Inst); Triumvira Immunologics, Inc (Inst); Unum Therapeutics (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Millennium (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Parexel International, LLC (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Vaccibody (Inst)
 
Daniel D. Karp
No Relationships to Disclose
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; iOnctura; Kelun Pharmaceuticals/Klus Pharma; Molecular Partners; Peptomyc
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Anthony Paul Conley
Consulting or Advisory Role - Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Ignyta (Inst); Iovance Biotherapeutics (Inst); MedImmune (Inst); NantHealth (Inst)
Travel, Accommodations, Expenses - Genentech
 
Frank Mott
No Relationships to Disclose
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Ying Fan
No Relationships to Disclose
 
Peng Peng
Employment - TransThera Sciences (Nanjing), Inc.
Leadership - TransThera Sciences (Nanjing), Inc.
 
Wendy J. Levin
Employment - WJ Levin Consulting
Consulting or Advisory Role - WJ Levin Consulting
 
Brenda Ngo
No Relationships to Disclose
 
Qinhua Cindy Ru
Stock and Other Ownership Interests - TransThera Biosciences
Consulting or Advisory Role - ABM (Inst); Cellular Biomedicine Group (Inst); Gene Quantum (Inst); Long Sky Industries Limited; Phanes Therapeutics (Inst); Purinomia (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - TransThera Biosciences (Inst)
 
Frank Wu
Employment - TransThera Biosciences
Leadership - TransThera Biosciences
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen